Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cell-based Therapy for Kidney Disease
NCT04187625Phase 1Unknown
- Sponsor
- Brigham and Women's Hospital
- Start
- Jan 2023
- Primary completion
- Jan 2024
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of autologous endothelial progenitor cells in chronic kidney disease (CKD), sponsored by Brigham and Women's Hospital. Primary endpoint: Safety of progenitor cell delivery at 180 days. Status: unknown.
02
Drugs
autologous endothelial progenitor cells
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04187625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04187625.